Advance Search

Evaluation of serum levels of visfatin and resistin alongside other biochemical indicators in breast cancer

Nahla Yassin Abdullah
Department of Clinical biochemistry, College of Health Science, Hawler Medical University, Kurdistan Region, Iraq.
Sardar Noury Ahmad
Department of Clinical biochemistry, College of Medicine, Hawler Medical University, Kurdistan Region, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2026 Nahla Yassin Abdullah , Sardar Noury Ahmad (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objective: One important modifiable risk factor for breast cancer is obesity. The pathophysiology and advancement of breast cancer are facilitated by the release of chemicals from obese adipose tissue, including proinflammatory and adipocytokines. The two adipocytokines that are the subject of this study are Resistin and Visfatin. To compare breast cancer patients' blood and tissue levels of Resistin, Visfatin, and other biochemical markers to those of healthy controls.

Methods: a case-control study involving breast cancer patients and healthy individuals. The study included 30 women patients with breast cancer before treatment, the same number (30) of women with breast cancer on treatment, and also 30 women in a healthy group, totally collected 90 female blood sample from patients that diagnosed with a breast cancer and healthy control, the level of serum Visfatin and Resistin with biochemical parameters was performed for all participants.

Results: The mean ± SE Visfatin levels in the patients (pre-treatment and post-treatment) were elevated (4.44 ± 0.807, 7.79 ± 1.802) relative to the control (3.53 ± 0.214). With a P-value of 0.025. There was a significant difference in the mean ± SE of serum Resistin levels between the cases and the control group with (P = 0.013).

Conclusion: According to our study, women with breast cancer had significantly greater levels of Visfatin and Resistin than those in good health. This implies that the genesis and progression of breast cancer may be influenced by these adipocytokines.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. AL-Yacoubi SS, AL-Izzi MH. Estimation of Serum Levels of Visfatin and Tumor Necrosis Factor-alpha in Iraqi Women with Breast Cancer. Egypt J Hosp Med. 2022;89(2):7925-8. https://doi.org/10.21608/ejhm.2022.277393
  2. Cuthrell KM, Tzenios N. Breast cancer: updated and deep insights. Int J Res Oncol. 2023;6(1):104-18. https://journalirjo.com/index.php/IRJO/article/view/129
  3. Kumie G, Melak T, Wondifraw Baynes H. The association of serum lipid levels with breast cancer risks among women with breast cancer at felege hiwot comprehensive specialized hospital, Northwest Ethiopia. Breast cancer Targets Ther. 2020:279-87. https://doi.org/10.2147/bctt.s279291
  4. Assiri AM, Kamel HF, Hassanien MF. Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre-and postmenopausal Saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015;2015(1):253519. https://doi.org/10.1155/2015/253519
  5. Motawi TM, Zakhary NI, Darwish HA, Abdullah HT, adros SA. Significance of some non-invasive biomarkers in the early diagnosis and staging of Egyptian breast cancer patients. Asian Pak J Cancer Prev. 2020;21(11):3279. https://doi.org/10.31557/apjcp.2020.21.11.3279
  6. Verras G-I, Tchabashvili L, Chlorogiannis D-D, Mulita F, Argentou M-I. Updated clinical evidence on the role of adipokines and breast cancer: a review. Cancers. 2023;15(5):1572. https://doi.org/10.3390/cancers15051572
  7. Piasecka K, Stanisławek A, Stasiak E, Irzmańska-Hudziak A, Kociuba-Adamczuk K. A case-control study of the lipid profile of women with breast cancer. J Educ Health Sport. 2020;10(2):41-9. https://doi.org/10.12775/jehs.2020.10.02.005
  8. Dalamaga M, Christodoulatos GS. Visfatin, obesity, and cancer. Adipocytokines, energy balance, and cancer. Springer; 2016. P. 109-36. https://doi.org/10.1007/978-3-319-41677-9_6
  9. Mir MM, Mir R, Alghamdi MAA, Wani JI, Sabah ZU, Jeelani M, et al. Differential association of selected adipocytokines, adiponectin, leptin, resistin, visfatin and chemerin, with the pathogenesis and progression of type 2 diabetes mellitus (T2DM) in the asir region of Saudi Arabia: A case control study. J Pers Med. 2022;12(5):735. https://doi.org/10.3390/jpm12050735
  10. Abedalrahman SK, Ali BM, Al-Khalidy NAI, Al-Hashimi AS. Risk factors of breast cancer among Iraqi women. J Contemp Med Sci. 2019;5(3). https://doi.org/10.22317/jcms.v5i3.609
  11. Cao J, Li J, Zhang Z, Qin G, Pang Y, Wu M, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14(1):4927. https://doi.org/10.1038/s41598-024-54762-x
  12. Abdulwahed A, Alkanaani M, Alsamarrai A, Hamad M, Dakheel A, Ahmed T, et al. Determination of some visfatin hormone level and lipid profilein some breast cancer patients in Samarra city. Ann Trop Med Public Health. 2020;23:S420. https://doi.org/10.36295/asro.2020.23134
  13. El-Benhawy SA, Abd El Moneim NA, Ebeid SA. Serum adipocytokines (visfatin and resistin): new biomarkers of breast cancer patients. Middle East J Cancer. 2015;6(4):253-65.
  14. Coskun T, Kosova F, Ari Z, Sakarya A, Kaya Y. Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer. Mol Clin Oncol. 2016;4(5):893-7. https://doi.org/10.3892/mco.2016.815
How to Cite
Abdullah , N. Y., & Ahmad, S. N. . (2026). Evaluation of serum levels of visfatin and resistin alongside other biochemical indicators in breast cancer. Zanco Journal of Medical Sciences (ZJMS), 30(1), 190–200. https://doi.org/10.15218/zjms.2026.014

Send mail to Author

Send Cancel